SNDL INC(NASDAQ:SNDL) stock Fundamental Analysis

Fundamental Rating

Overall SNDL gets a fundamental rating of 3 out of 10. We evaluated SNDL against 195 industry peers in the Pharmaceuticals industry. While SNDL seems to be doing ok healthwise, there are quite some concerns on its profitability. SNDL has a decent growth rate and is not valued too expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year SNDL has reported negative net income.

SNDL had a positive operating cash flow in the past year.

In the past 5 years SNDL always reported negative net income.

SNDL had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

SNDL's Return On Assets of -7.65% is fine compared to the rest of the industry. SNDL outperforms 74.73% of its industry peers.

SNDL has a better Return On Equity (-9.14%) than 77.42% of its industry peers.

		Industry Rank	Sector Rank
ROA	-7.65%
ROE	-9.14%
ROIC	N/A

ROA(3y)-16.37%

ROA(5y)-36.28%

ROE(3y)-18.99%

ROE(5y)-54.06%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 25.69%, SNDL is in line with its industry, outperforming 51.08% of the companies in the same industry.

SNDL's Gross Margin has improved in the last couple of years.

The Profit Margin and Operating Margin are not available for SNDL so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	25.69%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y16.95%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

SNDL does not have a ROIC to compare to the WACC, probably because it is not profitable.

SNDL has more shares outstanding than it did 1 year ago.

SNDL has more shares outstanding than it did 5 years ago.

The debt/assets ratio for SNDL is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of 1.39, we must say that SNDL is in the distress zone and has some risk of bankruptcy.

With a decent Altman-Z score value of 1.39, SNDL is doing good in the industry, outperforming 62.90% of the companies in the same industry.

The Debt to FCF ratio of SNDL is 4.58, which is a neutral value as it means it would take SNDL, 4.58 years of fcf income to pay off all of its debts.

SNDL has a Debt to FCF ratio of 4.58. This is amongst the best in the industry. SNDL outperforms 87.10% of its industry peers.

A Debt/Equity ratio of 0.10 indicates that SNDL is not too dependend on debt financing.

Looking at the Debt to Equity ratio, with a value of 0.10, SNDL is in line with its industry, outperforming 46.24% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.1
Debt/FCF	4.58
Altman-Z	1.39

ROIC/WACCN/A

WACC8.51%

2.3 Liquidity

SNDL has a Current Ratio of 5.61. This indicates that SNDL is financially healthy and has no problem in meeting its short term obligations.

SNDL has a better Current ratio (5.61) than 68.28% of its industry peers.

A Quick Ratio of 4.16 indicates that SNDL has no problem at all paying its short term obligations.

With a decent Quick ratio value of 4.16, SNDL is doing good in the industry, outperforming 61.29% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	5.61
Quick Ratio	4.16

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.42% over the past year.

SNDL shows a decrease in Revenue. In the last year, the revenue decreased by -1.49%.

Measured over the past years, SNDL shows a very strong growth in Revenue. The Revenue has been growing by 146.22% on average per year.

EPS 1Y (TTM)50.42%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%15.51%

Revenue 1Y (TTM)-1.49%

Revenue growth 3Y146.22%

Revenue growth 5YN/A

Sales Q2Q%-3.14%

3.2 Future

The Earnings Per Share is expected to grow by 29.73% on average over the next years. This is a very strong growth

Based on estimates for the next years, SNDL will show a small growth in Revenue. The Revenue will grow by 5.58% on average per year.

EPS Next Y44.07%

EPS Next 2Y46.14%

EPS Next 3Y32.74%

EPS Next 5Y29.73%

Revenue Next Year0.63%

Revenue Next 2Y2.42%

Revenue Next 3Y3.47%

Revenue Next 5Y5.58%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SNDL. In the last year negative earnings were reported.

SNDL is valuated quite expensively with a Price/Forward Earnings ratio of 64.84.

Based on the Price/Forward Earnings ratio, SNDL is valued a bit cheaper than 75.27% of the companies in the same industry.

Compared to an average S&P500 Price/Forward Earnings ratio of 96.58, SNDL is valued a bit cheaper.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	64.84

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, SNDL is valued a bit cheaper than 77.96% of the companies in the same industry.

85.48% of the companies in the same industry are more expensive than SNDL, based on the Price/Free Cash Flow ratio.

		Industry Rank	Sector Rank
P/FCF	20.44
EV/EBITDA	36.39

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.

SNDL's earnings are expected to grow with 32.74% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y46.14%

EPS Next 3Y32.74%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

SNDL does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SNDL INC

NASDAQ:SNDL (2/13/2025, 9:39:48 AM)

1.85

+0.03 (+1.65%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-05 2024-11-05/bmo

Earnings (Next)05-07 2025-05-07

Inst Owners14.39%

Inst Owner Change-79.98%

Ins Owners0.52%

Ins Owner ChangeN/A

Market Cap491.18M

Analysts82.5

Price Target3.32 (79.46%)

Short Float %1.59%

Short Ratio2.05

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-10.34%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)-0.6%

Revenue NQ rev (3m)-0.6%

Revenue NY rev (1m)0%

Revenue NY rev (3m)-0.08%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	64.84
P/S	0.77
P/FCF	20.44
P/OCF	15.87
P/B	0.58
P/tB	0.7
EV/EBITDA	36.39

EPS(TTM)-0.29

EYN/A

EPS(NY)0.03

Fwd EY1.54%

FCF(TTM)0.09

FCFY4.89%

OCF(TTM)0.12

OCFY6.3%

SpS2.4

BVpS3.18

TBVpS2.65

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-7.65%
ROE	-9.14%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	25.69%
FCFM	3.77%

ROA(3y)-16.37%

ROA(5y)-36.28%

ROE(3y)-18.99%

ROE(5y)-54.06%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y16.95%

GM growth 5YN/A

F-Score7

Asset Turnover0.63

Health

		Industry Rank	Sector Rank
Debt/Equity	0.1
Debt/FCF	4.58
Debt/EBITDA	8.4
Cap/Depr	17.02%
Cap/Sales	1.09%
Interest Coverage	N/A
Cash Conversion	302.17%
Profit Quality	N/A
Current Ratio	5.61
Quick Ratio	4.16
Altman-Z	1.39

F-Score7

WACC8.51%

ROIC/WACCN/A

Cap/Depr(3y)24.16%

Cap/Depr(5y)302.46%

Cap/Sales(3y)3.05%

Cap/Sales(5y)46.31%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)50.42%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%15.51%

EPS Next Y44.07%

EPS Next 2Y46.14%

EPS Next 3Y32.74%

EPS Next 5Y29.73%

Revenue 1Y (TTM)-1.49%

Revenue growth 3Y146.22%

Revenue growth 5YN/A

Sales Q2Q%-3.14%

Revenue Next Year0.63%

Revenue Next 2Y2.42%

Revenue Next 3Y3.47%

Revenue Next 5Y5.58%

EBIT growth 1Y43.07%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year109.68%

EBIT Next 3Y46.23%

EBIT Next 5Y31.73%

FCF growth 1Y191.21%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y246.71%

OCF growth 3YN/A

OCF growth 5YN/A

SNDL INC (SNDL) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens